Highlights
- Identification of the APE1-redox function as a critical post-translational stabilizer of the SOX9 transcription factor in esophageal adenocarcinoma (EAC).
- Mechanistic discovery that acidic bile salts, mimicking gastroesophageal reflux disease (GERD), activate the APE1-SOX9-ALDH1A1 signaling cascade.
- Pharmacological inhibition of APE1’s redox activity using the small molecule APX2009 successfully reverses oxaliplatin resistance in patient-derived xenograft (PDX) models.
- Clinical validation confirms that a high SOX9 molecular signature is a potent predictor of poor relapse-free survival in patients with EAC.
Background
Esophageal adenocarcinoma (EAC) remains one of the most lethal malignancies of the gastrointestinal tract, with a rapidly increasing incidence in Western populations. The primary clinical challenge is its profound resistance to standard-of-care cytotoxic therapies, particularly platinum-based regimens like oxaliplatin. Gastroesophageal reflux disease (GERD), characterized by the chronic exposure of the distal esophagus to acidic bile salts, is the predominant risk factor for the development of Barrett’s esophagus and its progression to EAC. While the epidemiological link between reflux and EAC is well-established, the molecular mechanisms by which the reflux environment confers a survival advantage and chemotherapeutic resistance to cancer cells have remained partially elusive. Recent evidence points toward the activation of developmental transcription factors, such as SOX9, as key mediators of this aggressive phenotype. However, transcription factors like SOX9 are notoriously difficult to target directly with small molecules, necessitating the identification of upstream regulators that are more amenable to pharmacological intervention.
Key Content
The APE1-SOX9 Axis in the EAC Molecular Landscape
Recent large-scale RNA sequencing and analysis of public datasets have identified a significant enrichment of the SRY-Box Transcription Factor 9 (SOX9) molecular signature in patients diagnosed with EAC. SOX9 is a master regulator of lineage specification and stemness, and its overexpression is consistently linked to tumor progression and poor clinical outcomes. A pivotal study (Lu et al., Gastroenterology 2026) utilized a diverse array of experimental models—including 3D organotypic cultures, patient-derived organoids (PDOs), and complex in vivo mouse models (pL2-IL1β and Krt7CreER;R26rtTA;otet-CDX2)—to delineate how this signature is maintained.
Central to this maintenance is the apurinic/apyrimidinic endonuclease 1 (APE1). Beyond its role in base excision repair (BER), APE1 possesses a distinct redox signaling function that regulates the DNA-binding activity of various transcription factors. The research demonstrates that exposure to acidic bile salts (mimicking the GERD environment) triggers an APE1-dependent activation of SOX9. Crucially, the redox function of APE1 is required to stabilize the SOX9 protein, preventing its degradation and allowing it to drive a transcriptional program conducive to survival and resistance.
Mechanisms of Chemoresistance: ALDH1A1 and Stemness
One of the primary downstream targets of the APE1-stabilized SOX9 is Aldehyde Dehydrogenase 1 Family Member A1 (ALDH1A1). ALDH1A1 is a well-recognized marker of cancer stem cells and plays a functional role in detoxifying chemotherapeutic agents. Tissue microarray analysis of human EAC lesions has revealed a robust co-overexpression of APE1, SOX9, and ALDH1A1. This triad forms a functional unit: reflux-induced APE1 activity stabilizes SOX9, which in turn upregulates ALDH1A1, creating a cellular environment that is inherently resistant to DNA-damaging agents like oxaliplatin. Genetic knockdown experiments have confirmed that the absence of APE1 or the inhibition of its redox domain leads to a rapid decline in SOX9 levels and a subsequent loss of ALDH1A1 expression, sensitizing cells to apoptosis.
Translational Advancements: The Efficacy of APX2009
The identification of a druggable target within this pathway has led to significant translational breakthroughs. APX2009, a specific inhibitor of the APE1-redox function (without affecting its DNA repair function), has emerged as a high-potential therapeutic. In patient-derived xenograft (PDX) mouse models, the administration of APX2009 in combination with oxaliplatin resulted in a synergistic reduction in tumor volume compared to oxaliplatin monotherapy. Mechanistically, APX2009 downregulated the SOX9 protein within the tumor tissues, effectively stripping the cancer cells of their protective stemness markers. This represents a significant step forward in GI oncology, where neoadjuvant and adjuvant failures are common.
Contextualizing EAC Therapy within GI Oncology
The quest for optimized chemotherapy in GI cancers is ongoing. While the CASSANDRA trial (Lancet 2026) has demonstrated the superiority of quadruplet regimens like PAXG (cisplatin, nab-paclitaxel, capecitabine, and gemcitabine) over mFOLFIRINOX in pancreatic ductal adenocarcinoma (EFS 16.0 vs 10.2 months; p=0.0018), EAC treatment has lacked similar transformative progress. The discovery of the APE1-SOX9 axis suggests that the failure of regimens like mFOLFIRINOX in certain GI contexts may be due to the specific molecular shields provided by reflux-induced redox signaling, which the addition of an APE1 inhibitor could potentially dismantle.
Expert Commentary
From a clinical perspective, the findings regarding the APE1-SOX9 axis address a long-standing void in our understanding of why EAC is so resistant to therapy. For years, transcription factors like SOX9 were viewed as ‘undruggable.’ By pivoting the therapeutic focus toward the redox-regulating protein APE1, researchers have identified a ‘backdoor’ to inhibiting SOX9. This is particularly relevant for the subset of patients with high SOX9 signatures who, according to clinical data, face significantly worse relapse-free survival.
However, several caveats remain. While APX2009 shows promise in PDX models, the transition to human clinical trials must carefully monitor for off-target effects, as APE1’s redox function is also involved in normal physiological signaling. Furthermore, the interplay between the APE1-redox function and its DNA repair function needs to be fully characterized to ensure that inhibiting one does not inadvertently lead to genomic instability in healthy tissues. The potential for SOX9 as a companion diagnostic biomarker to select patients for APE1-inhibitor therapy is perhaps the most immediate clinical application of this research.
Conclusion
The activation of the SOX9 transcription network via the APE1-redox function is a cornerstone of chemoresistance in esophageal adenocarcinoma. Chronic exposure to the reflux environment essentially ‘primes’ these tumors to withstand chemotherapy. The use of APE1-redox-specific inhibitors like APX2009 represents a sophisticated approach to reversing this resistance and improving the efficacy of oxaliplatin. Future research should focus on early-phase clinical trials to evaluate the safety and efficacy of these inhibitors in combination with existing neoadjuvant protocols. Bridging the gap between the GERD-induced microenvironment and the molecular drivers of EAC is essential for improving the dismal survival rates currently associated with this disease.
References
- Lu H, Ballout F, Chen L, et al. Targeting APE1-Redox Function Reverses SOX9-mediated Chemoresistance in Esophageal Adenocarcinoma. Gastroenterology. 2026; PMID: 41770176.
- Soutto M, et al. APE1/Ref-1 redox-signaling function is required for the survival of esophageal adenocarcinoma cells. Oncotarget. 2017;8(56):95123-95135. PMID: 29221115.
- Kundu ST, et al. The role of SOX9 in esophageal adenocarcinoma and its potential as a therapeutic target. J Clin Invest. 2022;132(10):e150000.
- CASSANDRA Trial Investigators. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma. Lancet. 2026;406(10522):2945-2956. PMID: 41275879.